NanoVibronix announces pact for clinical study of UroShield at UMich

NanoVibronix announced it has signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial RCT study of UroShield. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, “We are partnering with a team of distinguished researchers at the University of Michigan to further advance clinical evidence of the efficacy of UroShield. UroShield is cleared under the U.S. Food and Drug Administration’s FDA Enforcement Discretion, and we hope positive outcomes from this independent study will support an application to the FDA for permanent clearance. RCTs are considered the ‘gold standard’ in clinical research, and we are pleased to be working with the team at the University of Michigan.”